GLUE

Monte Rosa Therapeutics Stock Analysis

AI Rating

Fair
  • Quality2/10
  • Growth↑ 7/10
  • Value↓ 0/10
Monte Rosa Therapeutics sales and earnings growth
GLUE Growth
Good
  • Revenue Y/Y↑ 63.54%
  • EPS Y/Y↑ 53.06%
  • FCF Y/Y↓ -172.35%
Monte Rosa Therapeutics gross and profit margin trends
GLUE Profitability
Neutral
  • Gross margin ↑ 100.00%
  • EPS margin↓ -31.20%
  • ROIC 5Y↓ -34.73%
Monte Rosa Therapeutics net debt vs free cash flow
GLUE Risk
Great
  • Debt / Equity↓ 0.2
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Monte Rosa Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗